Overview

Panitumumab IRDye800 Optical Imaging Study

Status:
Completed

Trial end date:
2021-09-21

Target enrollment:

Participant gender:

Summary

Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.

Phase:

Phase 1

Details

Lead Sponsor:

Eben Rosenthal

Treatments:

Antibodies, Monoclonal
Panitumumab